The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib (A), in combination with encorafenib (E) and cetuximab (C) in patients (pts) with previously treated BRAF V600E mutant metastatic colorectal cancer (mCRC).
 
Jeanne Tie
Honoraria - Merck Serono; MSD Oncology
Consulting or Advisory Role - Arcus Biosciences (Inst); BeiGene; Daiichi Sankyo/Astra Zeneca (Inst); Gilead Sciences (Inst); Haystack Oncology; Illumina; MSD Oncology; Pierre Fabre; Roche; Takeda
Speakers' Bureau - MSD Oncology
Research Funding - Grail (Inst); Haystack Oncology (Inst); Pierre Fabre (Inst)
 
Marcos Melian
Honoraria - Amgen, Servier
Consulting or Advisory Role - Amgen, Servier, Merck
Speakers' Bureau - Amgen, Servier, Merck
Travel, Accommodations, Expenses - Amgen, Servier, Merck
 
Ana Ruiz-Casado
Consulting or Advisory Role - Amgen
Expert Testimony - Medtronic and Servier
Travel, Accommodations, Expenses - SERVIER
 
Lucjan Wyrwicz
Honoraria - BeiGene; BMS; MSD; SERVIER
Consulting or Advisory Role - Agenus; AstraZeneca; GlaxoSmithKline; SERVIER
Speakers' Bureau - BMS; MSD; SERVIER
Travel, Accommodations, Expenses - Amgen; SERVIER
 
Piotr Wysocki
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb/Medarex; Janssen; MSD Oncology; Pierre Fabre; Roche
Travel, Accommodations, Expenses - Gilead Sciences; Immunicom; Pierre Fabre
 
Patrick Stuebs
No Relationships to Disclose
 
Enrique Aranda
No Relationships to Disclose
 
Nuria Salas
Employment - Spanish national health system
 
Elena Elez
Honoraria - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; Janssen; Lilly; Medscape; Merck; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Sanofi/Aventis; Seagan; SERVIER; Takeda
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cure Teq AG; Janssen; Merck; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics Inc.; RIN Institute Inc.; Roche; Roche; Sanofi; Seagen; SERVIER; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bioncotech (Inst); Biontech Rna Pharmaceuticals GMBH (Inst); Biontech Small Molecules GMBH (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim Spain (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo Inc. (Inst); Debiopharm Group (Inst); Genentech (Inst); Gercor (Inst); HalioDx (Inst); Hoffmann-La-Roche Ltd. (Inst); Hutchison MediPharma (Inst); Hutchison MediPharma (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Menarini (Inst); Menarini (Inst); Merck (Inst); Merck Sharp&Dohme de España SA (Inst); Merus NV (Inst); Mirati Therapeutics (Inst); Nouscom SRL. (Inst); Novartis (Inst); Novartis Farmacéutica SA (Inst); Pfizer (Inst); PharmaMar (Inst); Pierre Fabre (Inst); PledPharma (Inst); Redx Pharma (Inst); Roche (Inst); Sanofi (Inst); Scandion Oncology (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); Taiho Pharma USA (Inst); Taiho Pharmaceutical (Inst); WntResearch (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; Janssen; Lilly; Medscape; Merck; Merck Serono; MSD; Novartis; Pfizer; Pierre fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Sanofi; Seagan; SERVIER; Takeda
 
Giuseppe Curigliano
Leadership - ESMO; ESMO; ESMO Open; European Society of Breast Cancer Specialists (EUSOMA=
Honoraria - Ellipses Pharma
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celcuity; Daichi-Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; GlaxoSmithKline; Guardant Health; Hengrui Therapeutics; Lilly; Menarini; Merck; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen; Veracyte
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daichii Sankyo; Pfizer; Roche/Genentech
 
Barbara Radecka
No Relationships to Disclose
 
Christine Parseghian
Consulting or Advisory Role - Amgen; Johnson & Johnson/Janssen
Research Funding - BioMed Valley Discoveries; Lilly; Verastem
 
Istvan Takacs
No Relationships to Disclose
 
Volker Heinemann
Stock and Other Ownership Interests - BioNTech SE
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Merck; MSD; Novartis; Oncosil; Pfizer; Pierre Fabre; Roche; Sanofi; Seagen; SERVIER; Sirtex Medical
Consulting or Advisory Role - Amgen; AstraZeneca; GlaxoSmithKline; Halozyme; Janssen; Merck; MSD; Nordic Bioscience; Oncosil; Pierre Fabre; Roche; Servier/Pfizer; TERUMO
Research Funding - Amgen (Inst); Merck (Inst); Roche (Inst); Servier (Inst)
Expert Testimony - Oncosil; Servier
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Merck; MSD; Nordic Bioscience
 
Grace Vandal
Employment - Zentalis
 
Nidal Huniti
Employment - Zentalis
 
Joana Vidal Barrul
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Pierre Fabre
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre
Travel, Accommodations, Expenses - Merck; Pierre Fabre